(AOF) – Euroapi (+5,97% to 3.44 euros) posts the strongest increase in the SBF120 and the SRD market after today’s announcement of a subcontracting agreement (Contract Manufacturing Organization, CMO) signed with a global animal health company. As part of this collaboration, the active ingredient specialist will provide its client with a major veterinary product. He specifies that the total expected value of the contract is of the order of 130 to 150 million euros, over the period 2025-2029.
“The signing of this major contract secures the long-term supply of this complex chemical molecule, essential in the veterinary field,” declares Ludwig de Mot, Managing Director. “It demonstrates the recognition of Euroapi’s know-how and the reliability of Contract Manufacturing Organization’s premium services provided to its customers.
Euroapi emphasizes that it has strong expertise in the field of animal health with numerous clients and products in its portfolio, such as “hormones, prostaglandins and complex synthetic molecules”. The global animal health market value was estimated at $41.8 billion in 2023, and is expected to reach $56.8 billion in 2030, with an average annual growth rate of 4.5%, according to Health for Animals , the professional organization of the sector.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.